This company has been marked as potentially delisted and may not be actively trading. Flex Pharma (FLKS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FLKS vs. AVTX, MRSN, PEPG, RNXT, AADI, CUE, CELU, CARM, NBRV, and ANEBShould you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include Avalo Therapeutics (AVTX), Mersana Therapeutics (MRSN), PepGen (PEPG), RenovoRx (RNXT), Aadi Bioscience (AADI), Cue Biopharma (CUE), Celularity (CELU), Carisma Therapeutics (CARM), Nabriva Therapeutics (NBRV), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "medical" sector. Flex Pharma vs. Its Competitors Avalo Therapeutics Mersana Therapeutics PepGen RenovoRx Aadi Bioscience Cue Biopharma Celularity Carisma Therapeutics Nabriva Therapeutics Anebulo Pharmaceuticals Avalo Therapeutics (NASDAQ:AVTX) and Flex Pharma (NASDAQ:FLKS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings. Which has preferable valuation & earnings, AVTX or FLKS? Flex Pharma has higher revenue and earnings than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$441K119.82-$31.54MN/AN/AFlex Pharma$840K15.91-$21.92MN/AN/A Is AVTX or FLKS more profitable? Avalo Therapeutics has a net margin of 0.00% compared to Flex Pharma's net margin of -1,208.42%. Flex Pharma's return on equity of -98.04% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -442.16% 122.99% Flex Pharma -1,208.42%-98.04%-83.37% Do analysts prefer AVTX or FLKS? Avalo Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 514.75%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than Flex Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Flex Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of AVTX or FLKS? 87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 14.4% of Flex Pharma shares are owned by institutional investors. 3.0% of Avalo Therapeutics shares are owned by insiders. Comparatively, 7.6% of Flex Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, AVTX or FLKS? Avalo Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Flex Pharma has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Does the media prefer AVTX or FLKS? In the previous week, Avalo Therapeutics had 3 more articles in the media than Flex Pharma. MarketBeat recorded 3 mentions for Avalo Therapeutics and 0 mentions for Flex Pharma. Avalo Therapeutics' average media sentiment score of 0.96 beat Flex Pharma's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Avalo Therapeutics Positive Flex Pharma Neutral Does the MarketBeat Community prefer AVTX or FLKS? Flex Pharma received 348 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 73.23% of users gave Flex Pharma an outperform vote while only 50.00% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformAvalo TherapeuticsOutperform Votes1350.00% Underperform Votes1350.00% Flex PharmaOutperform Votes36173.23% Underperform Votes13226.77% SummaryAvalo Therapeutics beats Flex Pharma on 9 of the 16 factors compared between the two stocks. Get Flex Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLKS vs. The Competition Export to ExcelMetricFlex PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.37M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E RatioN/A8.6727.1419.96Price / Sales15.91262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book1.456.597.064.69Net Income-$21.92M$143.75M$3.23B$248.14M Flex Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLKSFlex PharmaN/A$0.74+0.5%N/A+67.4%$13.37M$840K0.004AVTXAvalo Therapeutics3.6044 of 5 stars$4.82+5.7%$30.00+522.4%-57.3%$52.19M$441K0.0040News CoverageShort Interest ↓High Trading VolumeMRSNMersana Therapeutics4.1191 of 5 stars$0.41+4.1%$5.20+1,177.6%-83.2%$50.73M$34.01M-0.67150PEPGPepGen2.7538 of 5 stars$1.50-1.3%$7.67+411.1%-91.9%$49.08MN/A-0.5030Trending NewsGap DownRNXTRenovoRx2.9636 of 5 stars$1.34-2.2%$7.25+441.0%+29.5%$49.01M$240K-2.356Positive NewsShort Interest ↓AADIAadi Bioscience0.6014 of 5 stars$1.96+4.8%$1.67-15.0%+15.0%$48.41M$25.07M-0.8640Gap UpCUECue Biopharma4.4833 of 5 stars$0.63-0.5%$3.00+373.5%-56.5%$47.74M$7.99M-0.7060Gap DownCELUCelularity0.5268 of 5 stars$1.97-0.8%N/A-46.1%$47.06M$54.22M-0.74220News CoverageCARMCarisma Therapeutics3.3391 of 5 stars$1.11+389.4%$1.93+73.4%-51.4%$46.39M$19.96M-0.7120News CoverageGap DownHigh Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ANEBAnebulo Pharmaceuticals3.0985 of 5 stars$1.09-0.9%$5.50+404.6%-42.6%$44.78MN/A-3.894Positive News Related Companies and Tools Related Companies Avalo Therapeutics Competitors Mersana Therapeutics Competitors PepGen Competitors RenovoRx Competitors Aadi Bioscience Competitors Cue Biopharma Competitors Celularity Competitors Carisma Therapeutics Competitors Nabriva Therapeutics Competitors Anebulo Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLKS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flex Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Flex Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FLKS Stock Free FLKS Stock Alerts